We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NXSN:TASENextVison Stabilized Systems, Ltd. Analysis

Data as of 2026-05-22 - not real-time

ILA 27,870.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

NextVision Stabilized Systems is trading at 27,870, barely above its calculated support of 27,650, while the 14‑day RSI sits at 39, hinting at modest oversold pressure. The MACD is in a bearish configuration (line below signal) and the 30‑day volatility is elevated at roughly 63%, suggesting price swings could be sharp. Beta is slightly negative, indicating the stock moves independently of the broader market, and the overall trend is neutral, so short‑term direction is uncertain.
On the fundamentals side, the company posted an 86% revenue surge and enjoys robust gross (68%) and operating (57%) margins, backed by a strong cash pile of over 540 M ILA and minimal debt. Return on equity is impressive at 33%, yet valuation metrics are extreme – a P/E of 75 versus an industry average of 29 and a DCF fair value near 2,000 compared with the current price. The dividend yield of 0.64% is modest but appears sustainable given a payout ratio under 45%. Analysts rate the stock as a strong buy, but the disparity between price and intrinsic value underscores a significant overvaluation risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support level
  • Bearish MACD histogram
  • RSI indicating potential short‑term rebound

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Exceptional revenue and margin expansion
  • Substantial cash reserves and low debt
  • Significant overvaluation relative to peers and DCF

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Rapid growth in UAV and defense markets
  • High ROE and strong free cash flow generation
  • Sustainable dividend and solid balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth86.30%
Profit Margin60.80%
P/E Ratio75.7
ROE32.83%
ROA18.35%
Debt/Equity0.79
P/B Ratio41.7
Op. Cash FlowILA84.2M
Free Cash FlowILA36.0M
Industry P/E29.5

Technical Analysis

TrendNeutral
RSI39.1
SupportILA 27,650.00
ResistanceILA 35,170.00
MA 20ILA 30,923.50
MA 50ILA 32,378.40
MA 200ILA 21,812.10
MACDBearish
VolumeStable
Fear & Greed Index91.5

Valuation

Fair ValueILA 1,973.60
Target PriceILA 38,657.12
Upside/Downside38.71%
GradeOvervalued
TypeGrowth
Dividend Yield0.64%

Risk Assessment

Beta-0.18
Volatility62.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.